Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 6/20 | 0.73 |
| ▸ | DNMT3A | Q9Y6K1 | 5/20 | 0.73 |
| ▸ | DNMT3L | Q9UJW3 | 2/20 | 0.73 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.65 |
| ▸ | ACHE | P22303 | 1/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.65 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | KDM1A | O60341 | 1/20 | 0.59 |
| ▸ | MITF | O75030 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13113090 | 0.85 | MEN1 (0.79) | DNMT1DNMT3ADNMT3LHDAC3ACHE | |
| SCHEMBL12639121 | 0.83 | DNMT1 (0.92) | DNMT1DNMT3ADNMT3LHDAC3ACHE | |
| SCHEMBL12217951 | 0.82 | DNMT1 (0.95) | DNMT1DNMT3ADNMT3LHDAC3ACHE | |
| SCHEMBL13140149 | 0.82 | DNMT1 (0.95) | DNMT1DNMT3ADNMT3LHDAC3ACHE | |
| SCHEMBL27777741 | 0.81 | DNMT1 (0.57) | DNMT1DNMT3ADNMT3LHDAC3ACHE | |
| SCHEMBL1891738 | 0.81 | DNMT1 (0.75) | DNMT1DNMT3ADNMT3LHDAC3ACHE | |
| SCHEMBL29822716 | 0.81 | DNMT1 (0.75) | DNMT1DNMT3ADNMT3LHDAC3ACHE | |
| SCHEMBL12217987 | 0.81 | DNMT1 (0.78) | DNMT1DNMT3ADNMT3LHDAC3ACHE | |
| SCHEMBL12217976 | 0.80 | HTT (0.68) | DNMT1DNMT3ADNMT3LHDAC3ACHE | |
| SCHEMBL12240670 | 0.80 | HTT (0.68) | DNMT1DNMT3ADNMT3LHDAC3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120749-B2 | Quinoline derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-09-01 | — | — | US | disclosed |
| US-9120749-B2 | Quinoline derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-09-01 | — | — | US | disclosed |
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-08-22 | — | — | US | disclosed |
| EP-2597955-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012016082-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-02-02 | — | — | WO | disclosed |
| US-20110256092-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-7939546-B2 | Quinoline derivatives for modulating DNA methylation | SUPERGEN, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7790746-B2 | Quinoline derivatives for modulating DNA methylation | SUPERGEN, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790746-B2 | Quinoline derivatives for modulating DNA methylation | SUPERGEN, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100129320-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100129320-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20090285772-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090099106-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099106-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20080175814-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080175814-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | DNMT1 1/4885DNMT3A 2/4885DNMT3L 3/4885 |
| US-20110256092-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | DNMT1 1/4885DNMT3A 2/4885DNMT3L 3/4885 |
| US-20090285772-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | DNMT1 1/4885DNMT3A 2/4885DNMT3L 3/4885 |
| US-20090099106-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | DNMT1 1/4885DNMT3A 2/4885DNMT3L 3/4885 |
| US-20100129320-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | DNMT1 1/4885DNMT3A 2/4885DNMT3L 3/4885 |
| US-20130217671-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | MELK, NADK, NEK1 | DNMT1 2805/4885DNMT3A 2466/4885DNMT3L 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.